ClinicaliQ Trial Snapshot
- A Study of Brenipatide in Participants With Alcohol Use Disorder — Recruiting • Phase III • NCT07219953.
- Brenipatide tested against placebo over 56 weeks to assess whether it safely reduces alcohol use in people with alcohol use disorder.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks. Conditions: Alcohol Use Disorder Interventions: LY3537031, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 1100 participants